Publications by authors named "F J Sepe"
Exploring Sex Differences in Outcomes of Dual Antiplatelet Therapy for Patients With Noncardioembolic Mild-to-Moderate Ischemic Stroke or High-Risk Transient Ischemic Attack: A Propensity-Matched Analysis of the READAPT Study Cohort.
Stroke
December 2024
Background: Sex may impact clinical outcomes in patients with stroke treated with dual antiplatelet therapy (DAPT). We aimed to investigate the sex differences in the short-term outcomes of DAPT within a real-world population of patients with noncardioembolic mild-to-moderate ischemic stroke or high-risk transient ischemic attack.
Methods: We performed a propensity score-matched analysis from a prospective multicentric cohort study (READAPT [Real-Life Study on Short-Term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack]) by including patients with noncardioembolic mild-to-moderate stroke (National Institutes of Health Stroke Scale score of 0-10) or high-risk transient ischemic attack (age, blood pressure, clinical features, duration of transient ischemic attack, presence of diabetes [ABCD] ≥4) who initiated DAPT within 48 hours of symptom onset.
Article Synopsis
- Migraine with aura (MwA) is a painful disorder marked by neurological symptoms, predominantly visual, with unclear causes involving the trigeminovascular system and cortical spreading depression.* -
- The study analyzed data from 272 MwA patients, finding that most experienced typical aura symptoms, especially visual auras, and some reported relapses within 24 hours.* -
- Common treatments for aura included triptans, non-steroidal anti-inflammatory drugs, and nutraceuticals, which may help improve clinical management and understanding of MwA.*
Background: According to the literature, about one third of patients with brain ischemic symptoms lasting <24 h, which are classified as Transient ischemic attacks (TIAs) according to the traditional "time-based" definition, show the presence of acute ischemic lesions at neuroimaging. Recent evidence has shown that the presence of acute ischemic lesions at neuroimaging may impact on the outcome of patients with transient ischemic symptoms treated with dual antiplatelet treatment (DAPT). This uncertainty is even more compelling in recent years as short-term DAPT has become the standard treatment for any non-cardioembolic TIA or minor ischemic stroke.
View Article and Find Full Text PDFArticle Synopsis
- - Short-term dual antiplatelet treatment (DAPT) shows better effectiveness compared to single antiplatelet treatment (SAPT) for preventing secondary strokes in patients with mild to moderate strokes and high-risk TIAs, according to a study of 2016 patients.
- - Patients treated with DAPT had a higher likelihood of regaining pre-stroke neurological function within 90 days and showed more early neurological improvement compared to those on SAPT.
- - The study suggests that DAPT might be a safer and more effective option than SAPT in real-world settings, even for patients not fitting the criteria of major clinical trials.
Article Synopsis
- Small cell lung cancer (SCLC) is a fast-growing lung cancer type that responds well to certain treatments, but not all patients benefit, highlighting a need for new therapies and biomarkers.
- The study investigated how exosomes from the blood of SCLC patients can influence responses to chemoimmunotherapy by examining immune and tumor markers.
- Results showed that exosomes from patients who responded well to treatment significantly increased cancer cell death in lab tests, suggesting they could help understand the interaction between cancer and the immune system.